Skip to main content

NICE IDs

02/02/2026
ID6168: Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer
30/01/2026
ID6480: Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648)
26/01/2026
ID6403: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673)
22/01/2026
ID6420: Obinutuzumab with mycophenolate mofetil for treating lupus nephritis
22/01/2026
ID6485: Targeted-release budesonide for treating primary IgA nephropathy (review of TA937)
20/01/2026
ID6235: Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
20/01/2026
ID6310: Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer
02/01/2026
ID6369: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
23/12/2025
ID6369: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
23/12/2025
ID6369: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
16/12/2025
ID6211: Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma
16/12/2025
ID6291: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable
15/12/2025
ID4004: Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer
15/12/2025
ID6256: Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer
13/11/2025
ID6347: Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
22/10/2025
ID6202: Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma
16/10/2025
ID6452: Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
08/10/2025
ID6408: For treating moderate to severe chronic hand eczema
07/10/2025
ID6434: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
07/10/2025
ID6255: Cabotegravir for preventing HIV-1 in adults and young people
Follow AWTTC: